Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer
The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
= 10). Patients in the favorable cohort had high intratumoral CD8 T cell density and IFN-γ response gene signature and/or antigen-specific T cell responses. Two patients with a relatively low TMB had T cell responses against unique neoantigens. Moreover, six of nine patients in the favorable group are still alive at the time of analysis, with survival ranging from 33 to 54 months after treatment. All 10 patients in the unfavorable cohort have succumbed to their disease and had survival ranging from 0.6 to 10.3 months. Collectively, our data indicate that immunological correlates associated with effector T cell responses are observed in patients with metastatic prostate cancer who benefit from ICB.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, low TMB does not preclude generation of effective antigen responses, nor does high TMB guarantee response to ICT (130-132).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [131]
In the citing paper
“For example, it was shown that anti-CTLA4 therapy can induce effective neoantigen-specific T-cell responses in patients with prostate cancer, even in the background of low TMB (131).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [131]
In the citing paper
“Multiple studies have reported that tumors identified as having”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [131]
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
GSVA: gene set variation analysis for microarray and RNA-Seq data
Hänzelmann, S., Castelo, R., & Guinney, J. (2013) · BMC Bioinformatics · doi:10.1186/1471-2105-14-7 · Cited by 15,440 · cited 1×
“The variation of activity of each immune cell type across samples was estimated by gene set variation analysis (33).”
MethodA framework for variation discovery and genotyping using next-generation DNA sequencing data
DePristo, M. A., Banks, E., Poplin, R., Garimella, K. V., Maguire, J. R., Hartl, C., Philippakis, A. A., del Angel, G., Rivas, M. A., Hanna, M., et al. (2011) · Nature Genetics · doi:10.1038/ng.806 · Cited by 11,456
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802 · cited 2×
“The median number of nonsynonymous somatic mutations was 76 in the cohort of 27 patients (table S5), which was much lower compared to melanoma and NSCLC (median number of nonsynonymous somatic mutations about 200) (3, 22), but was consistent for prostate cancer (1, 23).”
BackgroundMismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609 · cited 2×
“Interferon-–responsive gene signature and tumor-infiltrating lymphocytes are associated with favorable responses to ipilimumab The presence of tumor-infiltrating lymphocytes and interferon- (IFN-)–responsive gene signatures have been shown to be predictive of responses to ICB (7, 8, 16, 17).”
Background
Cited by
Items 101–159 of 159
Weiner, A. B., Yu, C. Y., Kini, M., Liu, Y., Davicioni, E., Mitrofanova, A., Lotan, T. L., & Schaeffer, E. M. (2022) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-022-00547-0 · Cited by 6
Liu, N., Wu, T., Ma, Y., Cheng, H. S., Li, W., & Chen, M. (2022) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000001399 · Cited by 7
A “Tail” of Immunotherapy in Metastatic Prostate Cancer
Pachynski, R. K. (2020) · European Urology · doi:10.1016/j.eururo.2020.08.040 · Cited by 7
MHC-I binding affinity derived metrics fail to predict tumor specific neoantigen immunogenicityPreprint
Nibeyro, G., Girotti, M. R., Prato, L. B., Morón, G., Luján, H. D., & Fernández, E. A. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.03.14.484285 · Cited by 6
New approaches and prospects of immunotherapy and gene therapy for prostate cancer
Bibi, R., & Sarkar, K. (2024) · Journal of Translational Genetics and Genomics · doi:10.20517/jtgg.2023.50 · Cited by 7
Li, J., Liu, C., Qian, X., Wang, X., Sun, H., Wang, L., Xue, H., Song, Y., Liu, J., Zhao, Y., et al. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07944-y · Cited by 8
Unlocking the Microbial Symphony: The Interplay of Human Microbiota in Cancer Immunotherapy Response
Chacon, J. A., Faizuddin, F., McKee, J. C., Sheikh, A., Vasquez, V. M., Gadad, S. S., Mayer, G., Siby, S., McCabe, M. M., & Dhandayuthapani, S. (2025) · Cancers · doi:10.3390/cancers17050813 · Cited by 8
Wang, X., Wang, Z.-Q., Mu, Z.-Y., Zhu, L.-P., Zhong, C., & Guo, S. (2022) · Medicine · doi:10.1097/md.0000000000029715 · Cited by 7
Zhuo, M., Gorgun, F. M., Tyler, D. S., & Englander, E. W. (2020) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12943 · Cited by 6
Kato, Y. X., Yamamoto, G., Watanabe, Y., Yamane, Y., Mizutani, H., Kurimoto, F., Seike, M., Gemma, A., Akagi, K., & Sakai, H. (2021) · International Journal of Clinical Oncology · doi:10.1007/s10147-021-01893-0 · Cited by 6
Gorgun, F. M., Widen, S. G., Tyler, D. S., & Englander, E. W. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.701968 · Cited by 7
mtPCDI: a machine learning-based prognostic model for prostate cancer recurrence
Cheng, G., Xu, J., Wang, H., Chen, J., Huang, L., Qian, Z. R., & Fan, Y. (2024) · Frontiers in Genetics · doi:10.3389/fgene.2024.1430565 · Cited by 5
Zhang, G., & Luo, Y. (2021) · International Journal of General Medicine · doi:10.2147/ijgm.s336757 · Cited by 5
Jayakrishnan, R., Schafer, C. C., & Tan, S. (2023) · PubMed Central · Cited by 10
Shen, D., Peng, H., Xia, C., Deng, Z., Tong, X., Wang, G., & Qian, K. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.939070 · Cited by 5
Röbeck, P., Franzén, B., Ahlman, R. C., Dragomir, A., Auer, G., Jorulf, H., Jacobsson, S. P., Viktorsson, K., Lewensohn, R., Häggman, M., et al. (2023) · Cytopathology · doi:10.1111/cyt.13226 · Cited by 5
Recent advances and future prospects of immunotherapeutic approaches in prostate cancer
Wang, N., Wang, C., Cui, S., Zhao, K., Zhang, J., Zhang, L., Jia, Y., & Kong, F. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-07720-2 · Cited by 7
Unleashing the power of peptides in prostate cancer immunotherapy: mechanism, facts and perspectives
Li, X., Yang, F., Wang, M., Huang, X., Zeng, X., Zhou, L., Peng, S., & Zhang, J. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1478331 · Cited by 6
Wang, B., Xiang, Y., Fang, Z., Le, J., Yu, J., Chen, S., Li, D., Liang, G., & Pan, X. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1668188 · Cited by 8
Liu, D., Qin, Z., Yi, B., Xie, H., Liang, Y., Zhu, L., Yang, K., Xu, Y., & Zhang, H. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03477-0 · Cited by 4
Xiao, P., Li, Y., & Wang, D. (2021) · Medicine in Drug Discovery · doi:10.1016/j.medidd.2021.100116 · Cited by 4
Immunogenomic profiles associated with response to life-prolonging agents in prostate cancer
Conteduca, V., Brighi, N., Schepisi, G., & Giorgi, U. D. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02354-3 · Cited by 4
Chimeric antigen receptor-engineered (CAR)-T cell therapy for metastatic prostate cancer
Tharian, L. R., Verma, S., Feinberg, D. M., Parameswaran, R., & Gupta, S. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217986 · Cited by 6
Zhou, X., Cheng, S., Chen, Z., Zhang, J., Wang, J., Li, Q., & Zhou, X. (2024) · Neoplasia · doi:10.1016/j.neo.2024.101109 · Cited by 3
尧, 嘉., 孙, 荣., 周, 彬., & 孙, 向. (2025) · 临床医药循证研究 · doi:10.65140/ebcm202501.5 · Cited by 8
Biomarker-Driven Immunotherapy for Precision Medicine in Prostate Cancer
Ottini, A., Sepe, P., Beninato, T., Claps, M., Guadalupi, V., Verzoni, E., Giannatempo, P., Baciarello, G., de Braud, F., & Procopio, G. (2021) · Personalized Medicine · doi:10.2217/pme-2021-0079 · Cited by 6
Immunotherapeutic strategies and immunotherapy resistance in prostate cancer
Deb, A., Patel, N., Patel, P. A., Kilinc, E., Hachem, S., Elajami, M. K., & Mansour, E. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-16032-5.00010-5 · Cited by 4
Computational Methods for Predicting Key Interactions in T Cell–Mediated Adaptive Immunity
Ehrlich, R., Glynn, E., Singh, M., & Ghersi, D. (2024) · Annual Review of Biomedical Data Science · doi:10.1146/annurev-biodatasci-102423-122741 · Cited by 3
Jiang, Y., Montierth, M. D., Yu, K., Ji, S., Tran, Q., Liu, X., Lal, J. C., Guo, S., Wu, A., Dai, Y., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.07.03.601939 · Cited by 4
Comprehensive assessment of computational methods for cancer immunoediting
He, S., Sun, S., Liu, K., Pang, B., & Xiao, Y. (2025) · Cell Reports Methods · doi:10.1016/j.crmeth.2025.101006 · Cited by 2
Identification of key genes with differential correlations in prostate cancer
Chi, Z., Zhang, Y., Hong, X., Yang, T., Xu, Q., Lin, W., Zhang, Y., & Zhang, Y. (2025) · Aging · doi:10.18632/aging.206323 · Cited by 2
Fonseca, N. M., Roberts, M. E., & Wyatt, A. W. (2021) · Translational Andrology and Urology · doi:10.21037/tau-20-1205 · Cited by 3
Recent advancements in the cancer vaccines: A review
Kawish, S. M., Hilles, A. R., Sharma, S., Alam, M., Alimujiang, K., Iqbal, Z., Beg, S., Mahmood, S., & Mirza, M. A. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.106422 · Cited by 3
Pan, B., Zheng, X., Huang, Y., Wei, W., Xu, S., Chen, S., Yin, J., Zhang, Y., Li, J., & Zheng, M. (2025) · Journal of Ovarian Research · doi:10.1186/s13048-025-01755-7 · Cited by 2
Olsen, T. A., Barnum, K. J., Avigan, D., & Rosenblatt, J. M. (2025) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2025.101650 · Cited by 4
Hui, J., Wang, C., Miao, Y., Liu, R., & Xu, J. (2020) · Cancer Gene Therapy · doi:10.1038/s41417-020-00273-6 · Cited by 2
Nakken, S., Lilleby, W. A., Switlyk, M. D., Knudsen, K. E., Lilleby, O., Zhao, S., Kaveh, F., Ekstrøm, P. O., Urbanucci, A., & Hovig, E. J. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11050330 · Cited by 2
Current and Emerging Therapies for Neuroendocrine Prostate CancerPreprint
Stoyanova, T. I., Alabi, B. R., & Liu, S. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4060092 · Cited by 2
Roy, P., & Singh, K. P. (2023) · International review of cytology · doi:10.1016/bs.ircmb.2023.03.012 · Cited by 2
Cancer Immunotherapy in Sub-Saharan Africa: Current Landscape, Barriers and Strategic Directions
Teibo, J. O., Atiba, F. A., Adebesin, A. O., Olagunju, A. S., Teibo, T. K. A., Adegoke, A. M., Al‐Hajeili, M., & Batiha, G. E. (2025) · IntechOpen eBooks · doi:10.5772/intechopen.1012288 · Cited by 1
Nyame, D. K., Baye, V., Kamara, I. J., & Zhou, X. (2026) · Exploration of Drug Science · doi:10.37349/eds.2026.1008141 · Cited by 1
Huang, C.-H., Chen, J.-Y., Chang, H.-Y., Hong, W.-Z., Jiang, Y.-W., Lee, C., Wu, C.-H., Lin, Y.-S., Tsai, Y.-Y., Kao, W.-L., et al. (2026) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-026-04336-9 · Cited by 1
Role of tumor microenvironment in prostate cancer therapy resistance
Malak, L. A., Souki, M. S. A., Moubayed, I., Ghamlouche, F., & Abou-Kheir, W. G. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-16032-5.00014-2 · Cited by 1
Molecular biomarkers in pancreatic ductal adenocarcinoma
Tsuboi, J., Yamada, R., & HIROKAWA, Y. S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95114-2.00016-9 · Cited by 1
Tumor immunology and the application of immunotherapy in ovarian carcinoma
Paijens, S. T. (2021) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.182133606
Sharma, P., Anandhan, S., Siddiqui, B. A., Goswami, S., Subudhi, S. K., Gao, J., Peggs, K. S., Quezada, S. A., & Allison, J. P. (2022) · Wiley eBooks · doi:10.1002/9781119000822.hfcm068.pub2
Leveraging the Tumor Immune Microenvironment To Overcome Genitourinary Cancers
Bellone, M., & Mondino, A. (2023) · European Urology Oncology · doi:10.1016/j.euo.2023.04.002
Updates in Precision Oncology in Prostate and Urothelial Cancer
Brown, J. R. (2024) · International Journal of Cancer Care and Delivery · doi:10.53876/001c.94043
Coquan, E., Hervieu, A., Cropet, C., Saâda-Bouzid, E., Rouge, T. D. L. M., Lavaud, P., Meriaux, É., Borchiellini, D., Crouzet, L., Fuerea, A. C., et al. (2025) · Research Square · doi:10.21203/rs.3.rs-6062361/v1
Han, S., Shi, T., Liao, Y., Chen, D., Yang, F., Wang, M., Ma, J., Li, H., Xu, Y., Zhu, T., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26575070
Han, S., Shi, T., Liao, Y., Chen, D., Yang, F., Wang, M., Ma, J., Li, H., Xu, Y., Zhu, T., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26575073
Wang, L., Pan, S., Zhu, B., Yu, Z., & Wang, W. (2021) · Figshare · doi:10.6084/m9.figshare.14121708
Zhang, F., Xiong, Y., Luo, Z., Xue, Q., Wang, L., Fu, Q., Zhang, W., Pati-Alam, A., Okoli, U. A., & Zhang, G. (2026) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2026.2626084
PD-1/PD-L1 for prostate cancer: from clinical trials to practice
Holmes, A., Okobi, T., Arham, A., Vaishampayan, N., Subramanya, D., & Tagawa, S. T. (2026) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2026.2649610 · Cited by 2
Immune microenvironment and strategy of immunotherapy in acral melanoma
Minowa, T., Murata, K., Watowich, S. S., Gubin, M. M., & Hirohashi, Y. (2026) · Immunological Medicine · doi:10.1080/25785826.2026.2670041
Shon, H. W., Kim, S.-K., Kang, G., Lee, M. R., Lee, Y., Kang, S., Choi, S. I., Lee, J., Kim, D., & Kim, Y.-H. (2026) · International Journal of Hyperthermia · doi:10.1080/02656736.2026.2716349
Neoantigen in cancer immunotherapy: mechanism, therapeutic strategies and future perspectives
Raj, A., Khan, Z., Mumtaz, Mehan, S., Lamba, T., Pandoh, N., & Dayal, K. (2026) · Immunotherapy · doi:10.1080/1750743x.2026.2721185
Arginine methyltransferase PRMT3 suppresses tumor-intrinsic immunity via promoting cGAS methylation
Chen, Y., Liu, Y., Peng, J., Wang, X., Wei, Z., Yin, X., Zhai, X., Li, Y., Yu, J., & Meng, X. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218787
Tsimberidou, A. M., Cabanski, C. R., Drakaki, A., Khalil, D. N., Siddiqui, B. A., Basu, S., Okrah, K., Silva, D. M. D., Gautam, S., Alayli, F. A., et al. (2026) · Science Advances · doi:10.1126/sciadv.aee8730
Metadata
- Authors
- Subudhi, S. K., Vence, L., Zhao, H., Blando, J., Yadav, S. S., Xiong, Q., Reuben, A., Aparicio, A., Corn, P. G., Chapin, B. F., Pisters, L. L., Troncoso, P., Tidwell, R. S., Thall, P., Wu, C.-J., Zhang, J., Logothetis, C. L., Futreal, A., Allison, J. P., & Sharma, P.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
- Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
- Corresponding author
- Allison, James P.
- Sharma, Padmanee
- ORCID
- Subudhi, Sumit K.
- Vence, Luis
- Zhao, Hao
- Blando, Jorge
- Yadav, Shalini S.
- Xiong, Qing
- Reuben, Alexandre
- Aparicio, Ana
- Corn, Paul G.
- Chapin, Brian F.
- Pisters, Louis L.
- Troncoso, Patricia
- Tidwell, Rebecca Slack
- Thall, Peter
- Wu, Chang-Jiun
- Zhang, Jianhua
- Logothetis, Christopher L.
- Futreal, Andrew
- Allison, James P.
- Sharma, Padmanee
- Venue
- Science Translational Medicine
- Published
- 2020-04
- Volume
- 12
- Issue
- 537
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W3014592760
- Cited by
- 158
- References
- 36
- Citations by year
- 2026: 10 · 2025: 23 · 2024: 17 · 2023: 21 · 2022: 34 · 2021: 36 · 2020: 16
- FWCI
- 9.71
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Prostate Cancer Foundation
- University of Texas MD Anderson Cancer Center
- Stand Up To Cancer
- Parker Institute for Cancer Immunotherapy
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- ipilimumab, prostate cancer, neoantigens, immune checkpoint blockade, tumor mutational burden, CD8+ T cells, IFN-gamma response, antigen-specific T cell responses, metastatic prostate cancer, survival, immune correlates
- MeSH terms
- Antineoplastic Agents, Immunological, Ipilimumab, Humans, Male, Prostatic Neoplasms, Biomarkers, Tumor, Cohort Studies, CD8-Positive T-Lymphocytes
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.